Actively Recruiting
Evaluating the Safety and Effects of ISM5411 Tablets Compared to Placebo in Adults With Active Ulcerative Colitis
Led by InSilico Medicine Hong Kong Limited · Updated on 2026-10-29
80
Participants Needed
28
Research Sites
2 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ISM5411, an oral gut-restricted small-molecule prolyl hydroxylase PHD inhibitor, in adult patients with active ulcerative colitis. The study aims to assess the safety, tolerability, pharmacokinetics, and clinical effects of ISM5411, which may help protect the intestinal lining and reduce inflammation, addressing limitations of traditional anti-inflammatory drugs. This multicenter, randomized, double-blind, placebo-controlled trial focuses on adult patients aged 18 to 75 years. Participants are randomly assigned to one of four groups three groups receive ISM5411 tablets orally once a day for up to 12 weeks, and one group receives a placebo tablet orally once a day for up to 12 weeks. The study compares these groups to evaluate the effects and behavior of ISM5411 in the body. The trial includes various cohorts receiving the experimental drug or placebo, all administered as tablets once daily. During the study, participants undergo regular monitoring for safety and drug effects from week 1 to week 12, including tracking treatment-emergent adverse events, serious adverse events, and laboratory tests such as blood work, urinalysis, coagulation tests, and ECGs. Researchers also measure pharmacokinetic parameters like peak plasma concentration, elimination half-life, and colonic tissue concentration. The entire participation period extends up to 16 weeks, covering treatment and follow-up assessments.
CONDITIONS
Brief Title
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
Research Team
Y
Yang Deng
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here